Literature DB >> 26165407

Neurological Complications and Cataract in a Child With Thalassemia Major Treated With Deferiprone.

Nupur Parakh1, Rajni Sharma, Om Prakash, DeoNath Mahto, Bhavna Dhingra, Suvasini Sharma, Jagdish Chandra.   

Abstract

The oral iron chelator deferiprone is associated with various side effects including agranulocytosis, arthropathy, and deranged liver function tests. Rarely, neurological and visual side effects have been reported with high doses. The authors describe rare neurological manifestations of cerebellar ataxia, hypertonia, and bilateral cataract in an 11-year-old boy with thalassemia major on recommended therapeutic doses of deferiprone. The neurological abnormalities resolved with stoppage of deferiprone. Central nervous system toxicity and lenticular opacities may be attributed to the low molecular weight of deferiprone and its ability to cross the blood-brain and blood-ocular barrier, respectively. Clinicians should be alert to the possibility of neurological abnormalities that may occur during deferiprone therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165407     DOI: 10.1097/MPH.0000000000000391

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Iron is neurotoxic in retinal detachment and transferrin confers neuroprotection.

Authors:  Alejandra Daruich; Quentin Le Rouzic; Laurent Jonet; Marie-Christine Naud; Laura Kowalczuk; Jean-Antoine Pournaras; Jeffrey H Boatright; Aurélien Thomas; Natacha Turck; Alexandre Moulin; Francine Behar-Cohen; Emilie Picard
Journal:  Sci Adv       Date:  2019-01-09       Impact factor: 14.136

2.  Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.

Authors:  Raffaele Nuzzi; Giada Geronazzo; Federico Tridico; Alessia Nuzzi; Paolo Caselgrandi; Antonio Giulio Piga
Journal:  Clin Ophthalmol       Date:  2021-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.